Market Research Logo

Amryt Pharma plc (AMYT) - Financial and Strategic SWOT Analysis Review

Amryt Pharma plc (AMYT) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Amryt Pharma plc (Amryt) is a specialty pharmaceutical company that develops, manufactures and commercializes novel treatments for patients with rare and orphan diseases. It has two marketed products include Lojuxta for the treatment of adult HoFH and Episalvan for the treatment of PTW. The company is also developing a portfolio of pipeline candidates, AP101 and AP102 targeting multiple orphan diseases such as epidermolysis bullosa, acromegaly and Cushing’s disease. The company offers its products in European Economic Area (EEA) and Middle East. Amryt is headquartered in London, the UK.

Amryt Pharma plc Key Recent Developments

Apr 17,2018: Amryt Pharma: Final Results For the 12 months to 31 December 2017
Jan 24,2018: Amryt Pharma: Senior Management Team Appointment
Dec 20,2017: Amryt Pharma: Senior Management Team Appointment
Sep 04,2017: Amryt Pharma: Interim results for the six months ended 30 June 2017
Aug 30,2017: Amryt Pharma Announce the Appoints of Kieran Rooney

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Amryt Pharma plc - Key Facts
Amryt Pharma plc - Key Employees
Amryt Pharma plc - Key Employee Biographies
Amryt Pharma plc - Major Products and Services
Amryt Pharma plc - History
Amryt Pharma plc - Company Statement
Amryt Pharma plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Amryt Pharma plc - Business Description
Product Category: Imlan
Overview
Performance
Product Category: Lojuxta
Overview
Performance
Geographical Segment: EEA
Target Markets
Performance
Geographical Segment: Middle East
Performance
R&D Overview
Amryt Pharma plc - Corporate Strategy
Amryt Pharma plc - SWOT Analysis
SWOT Analysis - Overview
Amryt Pharma plc - Strengths
Amryt Pharma plc - Weaknesses
Amryt Pharma plc - Opportunities
Amryt Pharma plc - Threats
Amryt Pharma plc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Oil & Gas, Lifesciences Financial Deals and Alliances
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Amryt Pharma plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 17, 2018: Amryt Pharma: Final Results For the 12 months to 31 December 2017
Jan 24, 2018: Amryt Pharma: Senior Management Team Appointment
Dec 20, 2017: Amryt Pharma: Senior Management Team Appointment
Sep 04, 2017: Amryt Pharma: Interim results for the six months ended 30 June 2017
Aug 30, 2017: Amryt Pharma Announce the Appoints of Kieran Rooney
Aug 30, 2017: Amryt Appoints Kieran Rooney, Ph.D., as Vice President of Strategic Alliances and Licensing
Mar 30, 2017: Amryt Pharma Announces Final Results for the year ended 31 December 2016
Mar 27, 2017: Amryt Pharma Announces Senior Management Appointment
Feb 09, 2017: Amryt Pharma Announces Directorate Change
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Amryt Pharma plc, Key Facts
Amryt Pharma plc, Key Employees
Amryt Pharma plc, Key Employee Biographies
Amryt Pharma plc, Major Products and Services
Amryt Pharma plc, History
Amryt Pharma plc, Other Locations
Amryt Pharma plc, Subsidiaries
Amryt Pharma plc, Key Competitors
Amryt Pharma plc, Ratios based on current share price
Amryt Pharma plc, Annual Ratios
Amryt Pharma plc, Annual Ratios (Cont...1)
Amryt Pharma plc, Interim Ratios
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Amryt Pharma plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Amryt Pharma plc, Performance Chart (2013 - 2017)
Amryt Pharma plc, Ratio Charts
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report